Business context and reporting period
The supplied filing is Spherix Incorporated’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2016—not a Dominari Holdings Inc. filing. Spherix described itself as an intellectual-property monetization company focused on licensing and enforcing patent portfolios.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2016 | Nine months ended Sep. 30, 2016 |
|---|---|---|
| Revenue | $314,000 | $563,000 |
| Operating loss | $1.486 million | $4.669 million |
| Net loss | $446,000 | $2.573 million |
| Net income attributable to common stockholders | Not applicable; $446,000 loss | $28.907 million, including a $31.480 million deemed capital contribution tied to preferred-stock cancellation |
| Operating cash flow | $905,000 provided for the nine months |
- Revenue largely reflects deferred-revenue recognition under RPX patent-license agreements; the filing reports no meaningful revenue in the comparable 2015 periods.
- Third-quarter operating loss narrowed from $1.959 million in 2015 to $1.486 million in 2016. Nine-month operating loss fell from $46.378 million to $4.669 million, mainly because 2015 included a $37.212 million impairment charge.
- Nine-month other income was $2.096 million, including a $2.055 million favorable change in warrant-liability fair value. This noncash valuation gain should not be treated as recurring operating performance.
- At September 30, cash and cash equivalents were $303,000, marketable securities were $6.968 million, working capital was approximately $4.4 million, total assets were $15.563 million, and total liabilities were $6.551 million. Patent assets, net, were $8.201 million.
- The filing reports no conventional borrowings. Liabilities included $904,000 of warrant liabilities, $4.775 million of deferred revenue (current and long-term combined), and $274,000 of lease liabilities.
- Operating cash flow improved from $3.714 million used in the first nine months of 2015. The 2016 result included a $3.812 million increase in deferred revenue. Investing activities used $3.640 million; financing activities provided $2.896 million, including $2.140 million net from an August stock offering and $760,000 from warrant exercises.
Material changes, outlook, and risks
- In May 2016, Spherix granted RPX rights to sublicense patents to current RPX clients, receiving $4.355 million cash and cancellation of its remaining Series H preferred stock. The transaction also generated deferred revenue and a $31.480 million deemed capital contribution for EPS purposes. The August offering issued 1,592,357 common shares at $1.57 per share and raised approximately $2.1 million net.
- Spherix entered a patent-monetization arrangement with Equitable IP Corporation. Equitable had filed ten pending litigations; net monetization revenue is to be shared equally. Spherix retained the patents on its balance sheet and recognizes its share of eligible proceeds when received or otherwise earned.
- Management gave no quantified revenue or earnings guidance. It said it planned to pursue patent monetization, manage available funds, seek financing, and reduce expenses through collaboration where possible. The board and management were also evaluating strategic alternatives, without assurance that a transaction would result.
- Going concern: Management stated there was substantial doubt about Spherix’s ability to continue as a going concern. It said existing liquidity was insufficient to fund operations and other requirements for the foreseeable future and that additional financing and revenue generation would be needed; financing might not be available on favorable terms or at all.
- Legal and patent risks: The PTAB had found eight of 15 asserted claims of the ’599 patent and all asserted claims of patent 6,614,899 invalid in proceedings involving Uniden and VTech; Spherix appealed the ’599 decision. VTech’s case was dismissed with prejudice after a portfolio license. Uniden litigation remained stayed pending the appeal. FairPoint litigation was pending, while the Level 3/TW Telecom case was closed after Spherix sought dismissal without prejudice. Patent enforcement costs, adverse rulings, counterclaims, and contingent sharing obligations could materially affect results and liquidity.
- Controls and procedures: Management concluded disclosure controls were not effective at September 30, 2016, citing inadequate segregation of duties and insufficient controls to ensure all material transactions and developments were reflected in the financial statements. Remediation was still being developed.
- Other risks include dependence on patent monetization, possible further patent impairment, dilution from future equity financing, NASDAQ listing and share-price volatility, and potential payments to Rockstar from future recoveries.
Key facts for investors to verify
- Confirm the issuer and filing match the intended company: the source names Spherix Incorporated, whereas the request identifies Dominari Holdings Inc.
- Reconcile the nine-month $28.907 million income attributable to common stockholders with the $2.573 million net loss; the difference arises from the preferred-stock extinguishment accounting item, not operating earnings.
- Assess the quality and sustainability of reported operating cash flow, particularly the contribution from deferred revenue, and distinguish cash and marketable securities from cash available for operations.
- Check current financing needs and runway in light of the explicit going-concern warning, low cash balance, and stated need for additional capital.
- Verify the latest share count and potential dilution. The filing gives differing issued, outstanding, and later-date share figures, and reports substantial warrants, options, and restricted stock units.
- Review subsequent developments in the Uniden appeal and other patent cases, the Equitable arrangement, RPX license revenue recognition, and remediation of the disclosed material weakness.